Location History:
- Numazu, JP (1983 - 1985)
- Nagaizumi, JP (1990)
- Shizouka, JP (1990)
- Shimotogari, JP (1991)
- Machida, JP (1991 - 1995)
- Shizuoka, JP (1986 - 2000)
Company Filing History:
32 out of 730 
8 out of 45 
2 out of 104 
Years Active: 1983-2000
Areas of Expertise:
Title: Makoto Morimoto: A Pioneer in hG-CSF Polypeptide Innovations
Introduction
Makoto Morimoto, a distinguished inventor based in Shizuoka, Japan, holds an impressive portfolio of 44 patents. Renowned for his innovative contributions to the field of biomedicine, Morimoto's work primarily focuses on human granulocyte colony-stimulating factor (hG-CSF) polypeptide derivatives, showcasing his commitment to advancing medical science.
Latest Patents
Morimoto's latest patents revolve around novel hG-CSF polypeptide derivatives. These include modifications of the amino acid sequence of human granulocyte colony-stimulating factor by substituting or deleting specific amino acids. His patents detail recombinant plasmids containing DNA sequences that code for these derivatives, along with methods for producing them using microorganisms. Additionally, he has developed monoclonal antibodies that bind to the hG-CSF polypeptide derivatives, as well as chemically modified versions of hG-CSF and its derivatives. These innovations are crucial for enhancing therapeutic applications and improving patient outcomes.
Career Highlights
Throughout his career, Morimoto has made significant strides in biomedical research, particularly during his tenure at Kyowa Hakko Kogyo Co., Ltd., and Kyowa Hakko Kogyo Kabushiki Kaisha. His work has not only earned him numerous patents but has also positioned him as a leading figure in the development of therapeutic proteins. The practical applications of his inventions have promising implications for treatments related to immune deficiencies and various hematological conditions.
Collaborations
Collaboration has been a key aspect of Morimoto's success. He has worked alongside notable colleagues such as Tadashi Ashizawa and Masaji Kasai, further enriching the project outcomes through interdisciplinary teamwork. These collaborations have allowed for diverse insights and advancements in the field, significantly enhancing the quality of research and innovation.
Conclusion
Makoto Morimoto's contributions to the development of hG-CSF polypeptide derivatives exemplify his dedication as an inventor. With a substantial number of patents to his name and a track record of successful collaborations, Morimoto continues to influence the landscape of biomedicine. His innovations hold the potential to revolutionize treatments and improve lives, underscoring the vital role of inventors in advancing scientific knowledge.